16.11.2010 • NewsNovartisAlconNestlé

Novartis Hasn't Ruled out Keeping its 77% Alcon Stake

Swiss drugmaker Novartis  has not ruled out sticking with its 77% stake in U.S.-listed eyecare group Alcon, Novartis Chief Executive Joe Jimenez was quoted as saying on Tuesday.

"The intention is to have 100%. But Nestle owned 77%, and the company was run very successfully for many years, so we have not ruled that out," Jimenez said in an interview with the Financial Times published a day ahead of Novartis' investor day on Wednesday.

Novartis, which completed its buy of the 77% stake from Nestle earlier this year, is offering Alcon minority shareholders 2.8 Novartis shares for each Alcon share, an offer Alcon's Independent Director Committee has repeatedly rebuffed as too low.

Novartis has said it could use Swiss merger law to help it push through the deal.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.